Domain Therapeutics Administers First Doses in Innovative Phase I/II Cancer Trial with DT-7012 Domain Therapeutics has commenced dosing patients in a groundbreaking clinical trial of DT-7012, targeting CCR8 to address solid tumors. This therapy aims to enhance anti-tumor immunity effectively.

Domain Therapeutics Administers First Doses in Innovative Phase I/II Cancer Trial with DT-7012 #France #Strasbourg #Domain_Therapeutics #DT-7012 #CCR8

【Amazonサマーセール】ブラウンシェーバー洗浄液CCR8：深剃りを維持する秘訣 ブラウンシェーバー専用アルコール洗浄液CCR8で、常に清潔で快適なシェービング体験を。除菌、潤滑化、リフレッシュ効果で、シェーバーの性能を最大限に引き出し、肌への優しさも実現します。Amazon限定のお得な8個入り。

【Amazonサマーセール】ブラウンシェーバー洗浄液CCR8：深剃りを維持する秘訣 #ブラウン #シェーバー #CCR8

ブラウンシェーバー専用アルコール洗浄液CCR8で、常に清潔で快適なシェービング体験を。除菌、潤滑化、リフレッシュ効果で、シェーバーの性能を最大限に引き出し、肌への優しさも実現します。Amazon限定のお得な8個入り。

Expansion of multiple CD4+ T cell lineages in lymphocytic variant hypereosinophilic syndrome - PubMed These data provide further evidence for direct involvement of the aberrant T cell populations in disease pathogenesis in LHES and a rationale for further exploration of T cell-directed therapies.

#CHRS #ZLAB many others..... a non-oncology indication for anti- #CCR8? pubmed.ncbi.nlm.nih.gov/40350095/

Interaction between nasal epithelial cells and Tregs in allergic rhinitis responses to allergen via CCL1/CCR8 The airway epithelial barrier is the first defence against aeroallergens. Nasal epithelial cells (NECs) are vital in regulating innate and adaptive mucosal immunity in allergic rhinitis (AR). Tregs pr...

"CCL1/ #CCR8 may be the pathway between NECs and Tregs in vitro and may play a key role in the immune network of AR"... pmc.ncbi.nlm.nih.gov/articles/PMC...

Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells Accumulation of regulatory T (Treg) cells, an immunosuppressive population, limits the efficacy of immunotherapy in non-small cell lung cancer (NSCLC)…

#CHRS #BMY #ZLAB #CCR8 LM-108? >>depletion of CCR8+Treg cells combined with PD1 inhibitor extremely increased interleukin-12 secretion by the JAK-STAT pathway activation on CCL5+ DCs, thereby promoting cytotoxic activity of CD8+ T cells<< www.sciencedirect.com/science/arti....

#CCR8 companies presenting at #JPM2025.... #BMY #ZLAB #CHRS #BGNE #AMGN #BAYN.DE #ABBV #RHHBY #GILD

Which begs the question. It's now obvious that nobody is picking loqtorzi over keytruda for partnering. #CHRS just can't deliver on the promised stream of clinical trial supply deals. So, for #CCR8 and #IL-27, does loqtorzi deliver their promised flexibility, or paint them into a licensing corner?

1498 Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial Background CCR8 is an important chemokine receptor expressed on intratumoral regulatory T cell (Tregs). Selective depletion of intratumoral Tregs by targeting CCR8 may be a promising therapeutic appro...

The #CCR8 literature seems to be slowing down. Chinese companies leading info distribution, indication of prolonged stable disease with monotherapy (Qilu) and the very good LaNova results from a messy mix of three PD-1/LM-108 trials. Otherwise, nothing from #BMY. jitc.bmj.com/content/12/S...

The official website of Zhong Lun Law Firm 中伦律师律所官方网站

#CHRS #BMY #ZLAB LaNova licenses anti- #CCR8 LM-108 in China. Together with #MRK deal for LM-299 (PD-1/VEGF, $588m upfront), LaNova is swimming in cash. Who will get the U.S. license for 108? en.zhonglun.com/news/trade/5...

#CHRS here's some recent framing of the #CCR8 project, 2024 SITC annual meeting..... www.coherus.com/wp-content/u...